Monte Rosa Therapeutics, Inc. (GLUE) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
Monte Rosa Therapeutics, Inc. (GLUE)
A forensic read on Monte Rosa Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Grey Zone
Financial health
1.7
Altman Z-score
Clean
Earnings quality
4
Forensic signals
-41.0%
ROE
$1.9B
Market cap
Monte Rosa Therapeutics, Inc. earns a C (Mixed — selective) forensic quality grade, and its Altman Z-score is 1.7, placing it in the Grey zone. 4 forensic signals were flagged in its latest SEC filings, led by accruals ratio.
What the filings flag
+205.2%Accruals ratio.Net operating assets grew +205.2% relative to their average in FY2025 — the accrual component of earnings. Accruals are building sharply — a large slice of profit sits in operating assets, not cash; Richardson/Sloan link high accruals to weaker future returns as they reverse. The cash-flow cross-check agrees: reported earnings ran behind operating cash by -31% of net operating assets.
-17%Return on invested capital.Return on invested capital is -17% and rising from -34% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+25.3%/yrShare-count dilution.Diluted share count changed +76% over the last 3 years to FY2025 (+25.3%/yr). The count is GROWING — existing holders are being diluted. That's ~25.3% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~76%.
15% of revStock-based comp load.Stock-based compensation ran 15% of revenue in FY2025 — about $0.23 per diluted share. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
Key fundamentals
Net Margin-31.2%
Free Cash Flow$-27.5M
Latest Revenue$123.7M
Return on Equity-16.6%
Revenue Growth YoY+63.5%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Monte Rosa Therapeutics, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about GLUE's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown